A substantial body of literature indicates that inflammation plays a key role in mediating seizure-induced brain injury and epileptogenesis leading to a quest for novel inflammatory mediators as therapeutic targets for epilepsy. Cyclooxygenase-2 (COX-2) is among several key inflammatory factors known to promote seizure-induced brain inflammation. It is rapidly induced by seizures in select brain regions and known to promote seizure-induced neuronal loss, leukocyte infiltration, astrogliosis, microglial activation, and breakdown of the blood-brain barrier (BBB). COX-2 has been explored as a therapeutic target for neuroprotection in epilepsy using a variety of approaches (1). While global inhibition of COX2 by genetic or pharmacologic approaches was complicated by its early protective versus delayed deleterious role in seizure-induced brain injury, a greater clarity was observed in a conditional knock-out mouse in which the COX-2 gene was selectively deleted postnatally in forebrain neurons specifically upregulating COX-2 after seizures. Forebrain-specific conditional COX-2 knock-out mice demonstrated delayed neuroprotection, decreased release of inflammatory mediators, and BBB permeability after seizures (2). Prostaglandin E2 (PGE 2 ) is a major product of COX-2 in the brain and can activate four G-protein coupled receptors (GPCRs): EP1, EP2, EP3, and EP4. Whereas, PGE 2 is considered a crucial mediator of COX-2-induced events following seizures, what specific class of prostanoid receptors mediates seizure-induced inflammation and neuronal death is unknown and the subject of investigation by Jiang et al.
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In Basic Science Commentary A substantial body of literature indicates that inflammation plays a key role in mediating seizure-induced brain injury and epileptogenesis leading to a quest for novel inflammatory mediators as therapeutic targets for epilepsy. Cyclooxygenase-2 (COX-2) is among several key inflammatory factors known to promote seizure-induced brain inflammation. It is rapidly induced by seizures in select brain regions and known to promote seizure-induced neuronal loss, leukocyte infiltration, astrogliosis, microglial activation, and breakdown of the blood-brain barrier (BBB). COX-2 has been explored as a therapeutic target for neuroprotection in epilepsy using a variety of approaches (1) . While global inhibition of COX2 by genetic or pharmacologic approaches was complicated by its early protective versus delayed deleterious role in seizure-induced brain injury, a greater clarity was observed in a conditional knock-out mouse in which the COX-2 gene was selectively deleted postnatally in forebrain neurons specifically upregulating COX-2 after seizures. Forebrain-specific conditional COX-2 knock-out mice demonstrated delayed neuroprotection, decreased release of inflammatory mediators, and BBB permeability after seizures (2) . Prostaglandin E2 (PGE 2 ) is a major product of COX-2 in the brain and can activate four G-protein coupled receptors (GPCRs): EP1, EP2, EP3, and EP4. Whereas, PGE 2 is considered a crucial mediator of COX-2-induced events following seizures, what specific class of prostanoid receptors mediates seizure-induced inflammation and neuronal death is unknown and the subject of investigation by Jiang et al. (3) . Of the four receptors, EP2 receptor is expressed in both neurons and glia, and its activation is thought to promote inflammation and neurotoxicity in animal models of several neurodegenerative diseases. However, EP2 activation by PGE 2 has been shown to be neuroprotective after ischemia and to promote spatial learning (3, 4) .
In an effort to elucidate EP2's functions, Jiang et al. have previously utilized a high-throughput cell-based timeresolved fluorescence resonance energy transfer (TR-FRET) assay to identify selective allosteric potentiators of the human EP2 receptor, which conferred neuroprotection against NMDA-induced excitotoxicity in cultured hippocampal neurons (5) . These initial studies accompanied by the observation that EP2 activation has some pathological consequences such as potentiation of inflammatory responses, allowed them to hypothesize that pharmacologic blockade of the PGE 2 /EP2 signaling might represent an innovative approach to mitigate delayed inflammation and neuronal damage induced by prolonged status epilepticus (SE). In earlier studies, the group developed a brain-permeable small molecule EP2 antagonist (TG4-155) that completely suppressed the induction of COX-2 mRNA in cultured microglia by EP2 activation and significantly reduced hippocampal neuronal injury in mice following pilocarpine-induced SE. However,
Inhibition of the Prostaglandin Receptor EP2 Following Status Epilepticus Reduces Delayed Mortality and Brain
Inflammation. Jiang Prostaglandin E2 is now widely recognized to play critical roles in brain inflammation and injury, although the responsible prostaglandin receptors have not been fully identified. We developed a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2, TG6-10-1, with a sufficient pharmacokinetic profile to be used in vivo. We found that in the mouse pilocarpine model of status epilepticus (SE), systemic administration of TG6-10-1 completely recapitulates the effects of conditional ablation of cyclooxygenase-2 from principal forebrain neurons, namely reduced delayed mortality, accelerated recovery from weight loss, reduced brain inflammation, prevention of blood-brain barrier opening, and neuroprotection in the hippocampus, without modifying seizures acutely. Prolonged SE in humans causes high mortality and morbidity that are associated with brain inflammation and injury, but currently the only effective treatment is to stop the seizures quickly enough with anticonvulsants to prevent brain damage. Our results suggest that the prostaglandin receptor EP2 is critically involved in neuroinflammation and neurodegeneration, and point to EP2 receptor antagonism as an adjunctive therapeutic strategy to treat SE.
StEPing "EP2" to Prevent Status Epilepticus-Induced Mortality and Inflammation
this molecule had a relatively short half-life and a low brain to plasma ratio (3). In the current study, Jiang et al. overcame the unfavorable pharmacokinetic properties of TG4-155 with a novel compound, TG6-10-1, making significant headway in their efforts to develop a more potent EP2 antagonist for the therapeutic attenuation of SE-induced neuronal damage and associated morbidities. TG6-10-1 possessed a superior pharmacokinetic profile for in-vivo use coupled with high potency in the low nanomolar range for the EP2 receptor. Of importance, administration of TG6-10-1 four hours after SE demonstrated a wide variety of protective effects on neuroinflammation, mortality, and neurodegeneration following pilocarpine-induced SE. Notably, these effects were mediated without exerting an acute anticonvulsant effect (i.e., modifying SE).
Jiang et al. determined the potency of TG6-10-1 in C6G-EP2 cells by evaluating its effects using the TR-FRET assay, similar to their previous studies in which PGE2-induced cAMP accumulation in C6G cells overexpressing human EP2 receptor was monitored. The results indicated a competitive mechanism of antagonism by TG6-10-1for the EP2 receptor coupled with a 300-fold selectivity for the EP2 receptor compared with human EP3 and EP4 receptors. Additionally, it had negligible off-target effects in vitro. TG6-10-1 displayed a plasma half-life of approximately 1.6 hours and a brain to plasma ratio of 1.6 after systemic administration in mice, which was a significant improvement from its predecessors. Following the in-vitro studies, the authors proceeded to test the effect of TG6-10-1on EP2-receptor inhibition on pilocarpine-induced SE in C57BL/6 mice. Administration of the compound 4 hours after SE caused a significant increase in survival compared with the vehicle group, improving 1-week survival from 60 to 90% in addition to accelerating the recovery of lost weight after SE. Animals that were treated with the compound showed normal behavior 4 days after SE compared with vehicle-treated animals. These results reveal the beneficial effects of the EP2 antagonist on survival, weight loss, and improved functional recovery after pilocarpine-induced SE.
Next, the authors addressed whether TG6-10-1 attenuated brain proinflammatory response after pilocarpineinduced SE. To address this, the mRNA levels of a variety of cytokines and chemokines were measured in mice receiving either vehicle or the EP2 antagonist together with markers of gliosis in the hippocampi 4 days after SE. Administration of TG6-10-1 substantially decreased SE-induced increase in inflammatory markers, which supports EP2 receptor involvement in seizure-induced brain inflammation. The compound showed significant reduction in BBB breakdown following SE. Furthermore, treatment with the EP2 antagonist significantly decreased SE-induced neurodegeneration in the CA1, CA3, and hilar regions of the hippocampus as indicated by Fluoro-Jade B staining, strengthening the link between EP2-receptor activation and neuronal death following SE.
Finally, the authors investigated whether the beneficial effects of TG6-10-1 were caused by a direct anticonvulsant effect or a true anti-inflammatory effect. Two approaches were used to rule out TG6-10-1's ability to alter pilocarpineinduced SE. In the first approach, a pre-treatment paradigm demonstrated that the compound did not alter behavioral seizures or latency to onset of SE. A second post-treatment paradigm was employed in which the compound was administered after SE in animals monitored by continuous cortical EEG recordings. This study showed that TG6-10-1 did not change abnormal epileptiform activity over a 48-hour period or reentrance into seizure activity following recovery from pentobarbital.
Jiang et al. thus addressed an important question regarding the involvement of PGE 2 in mediating seizure-induced brain inflammation and neuronal injury. Their studies highlight the role of inflammation via the COX2-PGE2-EP2 receptor pathway in the neuropathology associated with pilocarpine-induced SE. The development of a more potent antagonist with improved in-vivo pharmacokinetic profile, which could be used as an adjunctive therapy to mitigate the effects of SE on neuroinflammation and neurodegeneration as well as delayed mortality, is a crucial achievement of this study. A secondary but very critical observation was that the compound did not have any direct anticonvulsant effect, which further reinforces their hypothesis. However, this work also brings forth several important unresolved issues. Given the literature suggesting an epileptogenic role of proinflammatory cytokines and neuroinflammation, it is curious that TG6-10-1 did not prevent epilepsy development in this study despite inhibiting several key proinflammatory cytokines. Since pilocarpine results in seizures by activation of cholinergic receptors and is used as a surrogate for nerve-agent toxicity, can these findings be generalized to nerve-agent neurotoxicity? Finally, since the authors noted beneficial behavioral effects in TG6-10-1-treated animals, will this translate to long-term improved cognitive function in animals treated with the compound? Answering these questions might further strengthen the case for targeting inflammation in epilepsy via EP2 activation.
The results bring to light a very significant mechanism by which COX-2 might be mediating inflammation and neuronal injury following prolonged seizures and further validate EP2-receptor inhibition as a therapeutic target. Since the long-term use of selective COX-2 inhibitors exerts adverse cardio-and cerebrovascular effects, the present study provides a potential avenue for the treatment of SE by EP2 inhibition. This article also exhibits a plausible mechanism by which PGE 2 exercises its effects on inflammation and neurodegeneration after SE. In summary, TG6-10-1 caused a decrease in inflammation and conferred neuroprotection in addition to improving survival, accelerating recovery of weight loss, and improving functional recovery thus opening up the possibility of using EP2 inhibition as an adjunctive therapy along with benzodiazepines to treat seizureinduced neuronal injury.
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